|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||47.58 - 48.17|
|52 Week Range||41.23 - 52.83|
|Beta (3Y Monthly)||0.78|
|PE Ratio (TTM)||19.49|
|Forward Dividend & Yield||1.25 (2.59%)|
|1y Target Est||53.90|
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
Sunnova Energy International Inc. set terms for its planned initial public offering, saying in a regulatory filing it plans to offer 17.6 million shares priced at $16 to $18 each. The Houston-based solar energy company would raise $316.8 million at the top of that range. Seven banks are underwriting the deal, led by BofA Merrill Lynch, JPMorgan and Goldman Sachs. Proceeds will be used to pay down debt and for general corporate purposes.
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Dividend paying stocks like Novo Nordisk A/S (CPH:NOVO B) tend to be popular with investors, and for good reason...
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
In the first-quarter earnings investor presentation, Novo Nordisk (NVO) guided for YoY operating profit growth of 2% to 5%.
OPEC Cuts Maintained, Putin and Bin Salman On Same Page Russia and Saudi Arabia agreed on an extension to the previous OPEC oil production cuts by 6 to 9 months. The meeting takes place today and tomorrow, July 1 and 2. The oil price environment since 2014 has pushed OPEC and Russia together somewhat, and […]The post Market Morning: OPEC Cuts, Trump & Xi Ceasefire, Apple Goes to China, Deutsche Bank Hiring appeared first on Market Exclusive.
Insider Monkey tracks hedge funds, billionaires, and prominent value investors for a very simple reason: their consensus picks generally outperform the market. We aren’t the only research shop broadcasting this fact using a bullhorn. Here is what strategist Ben Snider said in Goldman Sachs’ periodic hedge fund report: “Despite the strong track record of popular […]
Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. Here ...
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
The U.S. Food and Drug Administration on Monday approved Novo Nordisk's Victoza, a liraglutide injection, for the treatment of young patients 10 years or older with Type 2 diabetes. Although Victoza has been FDA-approved to treat adults with Type 2 diabetes since 2010, it is the only non-insulin drug approved for children other than metformin, which was approved for pediatric use in 2000. "Victoza has now been shown to improve blood sugar control in pediatric patients with Type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease," said Lisa Yanoff, acting director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. Type 2 diabetes occurs when the pancreas is unable to make enough insulin to keep blood sugar at normal levels. It's the most common form of diabetes, normally occurring in patients 45 years or older. However, in the past two decades, its prevalence among younger patients has dramatically risen. More than 5,000 new cases of Type 2 diabetes are now diagnosed each year in the U.S. among people younger than age 20, according to the Centers for Disease and Control and Prevention. Shares of Novo Nordisk have gained 10.8% so far this year, while the SPDR S&P Pharmaceuticals ETF has gained 3%. The Dow Jones Industrial Average has gained 11.8% and the S&P 500 has gained 15.3%.
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.